<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi> is a cytoprotective agent mainly used in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies, in order to ameliorate the toxic effects of anticancer chemotherapy and radiotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>In the past years an intriguing number of applications of <z:chebi fb="0" ids="2636">amifostine</z:chebi> have been identified; one of these is bone marrow cells protection and stimulation </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi> was administered in seven patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, four males and 3 females aged between 67 and 78 years old, in order to estimate its efficacy in reducing the need for red blood cells transfusions </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, four RA and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The drug was administered in an outpatient basis in a dose of 300 mgr/m2, three times weekly for at least four weeks </plain></SENT>
<SENT sid="5" pm="."><plain>We administered at the same time erythropoietin 10.000 U subcutaneously </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received daily supplementation of oral <z:chebi fb="0" ids="18248">ferrum</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> and <z:chebi fb="9" ids="27470">folic acid</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients, a woman with RA and two men, one with RA and another with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> improved the levels of Hb beyond 12,0 gr/dl and did not receive blood transfusions after the second week of treatment </plain></SENT>
<SENT sid="8" pm="."><plain>The drug was well tollerated without any side effects in <z:hpo ids='HP_0000001'>all</z:hpo> of the patients </plain></SENT>
</text></document>